CA2587270A1 - Early detection of sepsis - Google Patents
Early detection of sepsis Download PDFInfo
- Publication number
- CA2587270A1 CA2587270A1 CA002587270A CA2587270A CA2587270A1 CA 2587270 A1 CA2587270 A1 CA 2587270A1 CA 002587270 A CA002587270 A CA 002587270A CA 2587270 A CA2587270 A CA 2587270A CA 2587270 A1 CA2587270 A1 CA 2587270A1
- Authority
- CA
- Canada
- Prior art keywords
- sepsis
- analysis
- data
- clinical
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 147
- 238000001514 detection method Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 claims abstract description 53
- 208000015181 infectious disease Diseases 0.000 claims abstract description 50
- 238000005259 measurement Methods 0.000 claims abstract description 14
- 238000004458 analytical method Methods 0.000 claims description 72
- 238000013528 artificial neural network Methods 0.000 claims description 52
- 238000000684 flow cytometry Methods 0.000 claims description 44
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 38
- 238000003757 reverse transcription PCR Methods 0.000 claims description 36
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 30
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 30
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 30
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 30
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 29
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 28
- 102100032752 C-reactive protein Human genes 0.000 claims description 28
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 238000003745 diagnosis Methods 0.000 claims description 22
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 21
- 229940109239 creatinine Drugs 0.000 claims description 21
- 210000001616 monocyte Anatomy 0.000 claims description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 19
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 18
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 18
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 18
- 210000000440 neutrophil Anatomy 0.000 claims description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 17
- 239000004202 carbamide Substances 0.000 claims description 17
- 102000003814 Interleukin-10 Human genes 0.000 claims description 16
- 108090000174 Interleukin-10 Proteins 0.000 claims description 16
- 102100033467 L-selectin Human genes 0.000 claims description 16
- 210000001772 blood platelet Anatomy 0.000 claims description 16
- 102000000589 Interleukin-1 Human genes 0.000 claims description 15
- 108010002352 Interleukin-1 Proteins 0.000 claims description 15
- -1 CD 25 Proteins 0.000 claims description 14
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 14
- 108090001007 Interleukin-8 Proteins 0.000 claims description 12
- 239000000090 biomarker Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 11
- 238000007619 statistical method Methods 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 10
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 9
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 7
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims description 6
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims description 6
- 210000003714 granulocyte Anatomy 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract description 22
- 108090000695 Cytokines Proteins 0.000 abstract description 22
- 230000004913 activation Effects 0.000 abstract description 12
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 35
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 33
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 33
- 239000011159 matrix material Substances 0.000 description 27
- 102000004889 Interleukin-6 Human genes 0.000 description 21
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 19
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 19
- 230000001186 cumulative effect Effects 0.000 description 18
- 102000000018 Chemokine CCL2 Human genes 0.000 description 17
- 206010040070 Septic Shock Diseases 0.000 description 17
- 238000012549 training Methods 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000036303 septic shock Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 238000011068 loading method Methods 0.000 description 12
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 9
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 238000007477 logistic regression Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000003062 neural network model Methods 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 6
- 238000013145 classification model Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 206010053159 Organ failure Diseases 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000617 superantigen Toxicity 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 101100028900 Caenorhabditis elegans pcs-1 gene Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 3
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002095 exotoxin Substances 0.000 description 3
- 231100000776 exotoxin Toxicity 0.000 description 3
- 230000027950 fever generation Effects 0.000 description 3
- 230000008073 immune recognition Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 206010006500 Brucellosis Diseases 0.000 description 2
- 206010009192 Circulatory collapse Diseases 0.000 description 2
- 238000001134 F-test Methods 0.000 description 2
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 208000034784 Tularaemia Diseases 0.000 description 2
- 102400000084 Tumor necrosis factor ligand superfamily member 6, soluble form Human genes 0.000 description 2
- 101800000859 Tumor necrosis factor ligand superfamily member 6, soluble form Proteins 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008568 cell cell communication Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940124446 critical care medicine Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- YBUJMZKTOUBMGW-UHFFFAOYSA-N 5-(2-aminopyrimidin-4-yl)-2-tert-butyl-4-[3-[[ethyl(methyl)sulfamoyl]amino]-2-fluorophenyl]-1,3-thiazole Chemical compound CCN(C)S(=O)(=O)Nc1cccc(-c2nc(sc2-c2ccnc(N)n2)C(C)(C)C)c1F YBUJMZKTOUBMGW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 101710111216 Activated RNA polymerase II transcriptional coactivator p15 Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010058873 Anthrax sepsis Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 238000011546 CRP measurement Methods 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032134 Catastrophic Illness Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001077419 Damas Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100362789 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-17 gene Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010058889 Plague sepsis Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 101710180646 Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012124 rapid diagnostic test Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013468 resource allocation Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Evolutionary Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Artificial Intelligence (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Public Health (AREA)
- Software Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0426982.5 | 2004-12-09 | ||
| GBGB0426982.5A GB0426982D0 (en) | 2004-12-09 | 2004-12-09 | Early detection of sepsis |
| PCT/GB2005/004755 WO2006061644A1 (en) | 2004-12-09 | 2005-12-09 | Early detection of sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2587270A1 true CA2587270A1 (en) | 2006-06-15 |
Family
ID=34073429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002587270A Abandoned CA2587270A1 (en) | 2004-12-09 | 2005-12-09 | Early detection of sepsis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080114576A1 (enExample) |
| EP (2) | EP2458517A1 (enExample) |
| JP (1) | JP2008522604A (enExample) |
| CN (1) | CN101076806B (enExample) |
| AU (1) | AU2005313114B2 (enExample) |
| CA (1) | CA2587270A1 (enExample) |
| GB (1) | GB0426982D0 (enExample) |
| WO (1) | WO2006061644A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9053222B2 (en) | 2002-05-17 | 2015-06-09 | Lawrence A. Lynn | Patient safety processor |
| US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
| US8068990B2 (en) * | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| ATE472611T1 (de) * | 2005-11-25 | 2010-07-15 | Trinity College Dublin | Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression |
| JP4661870B2 (ja) | 2005-12-14 | 2011-03-30 | 日本電気株式会社 | ディジタル通信システム、屋内装置及び屋外装置 |
| GB0610078D0 (en) * | 2006-05-20 | 2006-06-28 | Secr Defence | Sepsis detection microarray |
| EP1950310A1 (en) * | 2007-01-23 | 2008-07-30 | Charite-Universitätsmedizin Berlin | Method for risk prediction of a postoperative sepsis in a human |
| GB0722582D0 (en) * | 2007-11-16 | 2007-12-27 | Secr Defence | Early detection of sepsis |
| WO2009123737A2 (en) | 2008-04-03 | 2009-10-08 | Becton, Dickinson And Company | Advanced detection of sepsis |
| EP2283443A1 (en) | 2008-05-07 | 2011-02-16 | Lynn, Lawrence A. | Medical failure pattern search engine |
| US11728041B2 (en) * | 2008-05-07 | 2023-08-15 | Lawrence A. Lynn | Real-time time series matrix pathophysiologic pattern processor and quality assessment method |
| EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
| US10460408B2 (en) * | 2009-01-31 | 2019-10-29 | Mayo Foundation For Medical Education And Research | Presentation of critical patient data |
| JP5667353B2 (ja) | 2009-09-25 | 2015-02-12 | シスメックス株式会社 | 血球計数装置、診断支援装置、診断支援方法及びコンピュータプログラム |
| ES2539854T3 (es) * | 2010-03-02 | 2015-07-06 | F. Hoffmann-La Roche Ag | Diagnóstico y predicción precoces basados en la detección de IL-6 del síndrome de respuesta inflamatoria sistémica y sepsis en pacientes asintomáticos |
| US9719842B2 (en) * | 2010-07-06 | 2017-08-01 | Norman A. Paradis | Method for the discovery, validation and clinical application of multiplex biomarker algorithms based on optical, physical and/or electromagnetic patterns |
| EP2643483A4 (en) * | 2010-11-26 | 2014-04-30 | Immunexpress Pty Ltd | DIAGNOSTIC AND / OR SCREENING APPROPRIATIONS AND USES THEREFOR |
| WO2014068018A1 (en) * | 2012-10-30 | 2014-05-08 | Abbott Gmbh & Co.Kg | Methods of prognosis and diagnosis of sepsis |
| US9953453B2 (en) | 2012-11-14 | 2018-04-24 | Lawrence A. Lynn | System for converting biologic particle density data into dynamic images |
| US10354429B2 (en) | 2012-11-14 | 2019-07-16 | Lawrence A. Lynn | Patient storm tracker and visualization processor |
| US20150362509A1 (en) * | 2013-01-28 | 2015-12-17 | Vanderbilt University | Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS) |
| WO2014134460A1 (en) | 2013-02-28 | 2014-09-04 | Lynn Lawrence A | Time lapsable motion image responsive to features of pathophysiologic perturbations |
| KR101595784B1 (ko) * | 2013-05-31 | 2016-02-26 | 가톨릭대학교 산학협력단 | 패혈증 고위험군 예측 방법 및 시스템 |
| JP2016526888A (ja) * | 2013-06-28 | 2016-09-08 | アキュメン リサーチ ラボラトリーズ プライヴェット リミテッドＡｃｕｍｅｎ Ｒｅｓｅａｒｃｈ Ｌａｂｏｒａｔｏｒｉｅｓ Ｐｔｅ． Ｌｔｄ． | 敗血症バイオマーカー及びそれらの使用 |
| US10260111B1 (en) * | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
| GB201402293D0 (en) * | 2014-02-11 | 2014-03-26 | Secr Defence | Biomarker signatures for the prediction of onset of sepsis |
| US11058332B2 (en) * | 2014-09-26 | 2021-07-13 | Sofradim Production | System and method for early detection of post-surgery infection |
| US10761093B2 (en) | 2014-10-09 | 2020-09-01 | Texas Tech University System | Microdevice for cell separation utilizing activation phenotype |
| US10832134B2 (en) | 2015-12-10 | 2020-11-10 | Deepmind Technologies Limited | Augmenting neural networks with external memory |
| EP3408773B1 (en) * | 2016-01-28 | 2023-09-20 | Beckman Coulter, Inc. | Infection detection and differentiation systems and methods |
| SG11201807719SA (en) * | 2016-03-23 | 2018-10-30 | Peach Intellihealth Inc | Use of clinical parameters for the prediction of sirs |
| EP3806712A1 (en) * | 2018-06-15 | 2021-04-21 | Beckman Coulter, Inc. | Method of determining sepsis in the presence of blast flagging |
| CN111374639A (zh) * | 2018-12-28 | 2020-07-07 | 陈柏龄 | 败血症的菌种预测系统与方法 |
| KR102287968B1 (ko) * | 2019-03-29 | 2021-08-09 | 연세대학교 산학협력단 | 균혈증 발병 위험도 예측 방법 및 이를 이용한 균혈증 발병 위험도 예측용 디바이스 |
| US20220299511A1 (en) * | 2019-06-17 | 2022-09-22 | The Broad Institute, Inc. | Immune cell signature for bacterial sepsis |
| JP7657195B2 (ja) * | 2019-07-12 | 2025-04-04 | ベックマン コールター， インコーポレイテッド | 収縮期血圧、血液パラメーター、およびこれらの組み合わせを含むバイタルサインを使用して敗血症を検出する方法 |
| EP4010682B1 (en) * | 2019-08-06 | 2024-07-17 | Beckman Coulter, Inc. | Detecting and reporting subpopulations of neutrophils |
| US20210059597A1 (en) * | 2019-08-30 | 2021-03-04 | Hill-Rom Services, Inc. | Sepsis monitoring system |
| WO2021102776A1 (zh) * | 2019-11-28 | 2021-06-03 | 北京肿瘤医院(北京大学肿瘤医院) | 一种用于早期体腔内感染性并发症诊断的标记物及方法 |
| JP7754815B2 (ja) * | 2019-12-27 | 2025-10-15 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン，インコーポレイテッド | 敗血症を患う個体における重症疾患の予測及び対処 |
| WO2021142479A1 (en) * | 2020-01-10 | 2021-07-15 | Prenosis, Inc. | A tool for selecting relevant features in precision diagnostics |
| JP7708769B2 (ja) * | 2020-01-10 | 2025-07-15 | プレノシス，インコーポレイテッド | ストリーミングデータ環境のための時間依存トリガ |
| CN114167062B (zh) * | 2020-09-10 | 2024-02-02 | 北京肿瘤医院(北京大学肿瘤医院) | 一种用于早期腹腔内感染性并发症诊断的标记物及方法 |
| TWI803893B (zh) * | 2021-06-28 | 2023-06-01 | 中國醫藥大學 | 敗血症之人工智慧輔助醫療診斷方法及其系統 |
| DE102022114248A1 (de) * | 2022-06-07 | 2023-12-07 | TCC GmbH | Verfahren sowie Vorhersagesystem zur Ermittlung der Eintrittswahrscheinlichkeit einer Sepsis eines Patienten |
| CN120526862A (zh) * | 2025-07-24 | 2025-08-22 | 中国疾病预防控制中心传染病预防控制所 | 一种基于5种标记物的感染病原体类型检测系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190872B1 (en) * | 1994-05-06 | 2001-02-20 | Gus J. Slotman | Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method |
| US6804551B2 (en) * | 1998-03-17 | 2004-10-12 | University Of Virginia Patent Foundation | Method and apparatus for the early diagnosis of subacute, potentially catastrophic illness |
| AU5900299A (en) * | 1998-08-24 | 2000-03-14 | Emory University | Method and apparatus for predicting the onset of seizures based on features derived from signals indicative of brain activity |
| WO2000052472A1 (en) | 1999-03-01 | 2000-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for infection in small children |
| DE10155600B4 (de) * | 2001-11-09 | 2009-08-27 | Oligene Gmbh | Nukleinsäure-Array |
| US20040038201A1 (en) * | 2002-01-22 | 2004-02-26 | Whitehead Institute For Biomedical Research | Diagnostic and therapeutic applications for biomarkers of infection |
| US7774143B2 (en) * | 2002-04-25 | 2010-08-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states |
| MXPA05005073A (es) * | 2002-11-12 | 2005-11-17 | Becton Dickinson Co | Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. |
| CA2505921A1 (en) * | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| MXPA05005072A (es) * | 2002-11-12 | 2005-07-22 | Becton Dickinson Co | Diagnostico de la sepsis o sirs usando perfiles de biomarcadores. |
| EP1673465A4 (en) * | 2003-09-29 | 2008-04-30 | Biosite Inc | PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS |
| TW200519384A (en) * | 2003-12-12 | 2005-06-16 | We Gene Technologies Inc | Sepsis detection chip and fabricating method thereof and method of detecting sepsis |
| US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| GB0610078D0 (en) * | 2006-05-20 | 2006-06-28 | Secr Defence | Sepsis detection microarray |
-
2004
- 2004-12-09 GB GBGB0426982.5A patent/GB0426982D0/en not_active Ceased
-
2005
- 2005-12-09 EP EP11008209A patent/EP2458517A1/en not_active Withdrawn
- 2005-12-09 CN CN2005800424703A patent/CN101076806B/zh not_active Expired - Fee Related
- 2005-12-09 WO PCT/GB2005/004755 patent/WO2006061644A1/en not_active Ceased
- 2005-12-09 US US11/792,724 patent/US20080114576A1/en not_active Abandoned
- 2005-12-09 JP JP2007544987A patent/JP2008522604A/ja active Pending
- 2005-12-09 CA CA002587270A patent/CA2587270A1/en not_active Abandoned
- 2005-12-09 EP EP05825137A patent/EP1839218A1/en not_active Withdrawn
- 2005-12-09 AU AU2005313114A patent/AU2005313114B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB0426982D0 (en) | 2005-01-12 |
| US20080114576A1 (en) | 2008-05-15 |
| AU2005313114A1 (en) | 2006-06-15 |
| EP2458517A1 (en) | 2012-05-30 |
| WO2006061644A1 (en) | 2006-06-15 |
| AU2005313114B2 (en) | 2012-01-19 |
| CN101076806B (zh) | 2012-01-11 |
| EP1839218A1 (en) | 2007-10-03 |
| CN101076806A (zh) | 2007-11-21 |
| JP2008522604A (ja) | 2008-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005313114B2 (en) | Early detection of sepsis | |
| Cheng et al. | A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection | |
| Darden et al. | Single-cell RNA-seq of human myeloid-derived suppressor cells in late sepsis reveals multiple subsets with unique transcriptional responses: a pilot study | |
| Sweeney et al. | Benchmarking sepsis gene expression diagnostics using public data | |
| US8131475B2 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
| US7640114B2 (en) | Method of diagnosis of cancer based on gene expression profiles in cells | |
| Jacobs et al. | Emerging infection and sepsis biomarkers: will they change current therapies? | |
| JP2017506510A (ja) | 敗血症の発症を予測するための装置、キット及び方法 | |
| US20050164231A1 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
| JP2018514189A (ja) | 敗血症の診断法 | |
| CN112331344B (zh) | 免疫状态评估方法及应用 | |
| WO2013119871A1 (en) | A multi-biomarker-based outcome risk stratification model for pediatric septic shock | |
| Sparks et al. | A unified metric of human immune health | |
| Penatzer et al. | Demographics to define pediatric burn patients at risk of adverse outcomes | |
| Kreitmann et al. | Mortality prediction in sepsis with an immune-related transcriptomics signature: A multi-cohort analysis | |
| WO2008089832A1 (en) | Method for risk prediction of a postoperative sepsis in a human | |
| WO2009063249A2 (en) | Early detection of sepsis | |
| Faix | Established and novel biomarkers of sepsis | |
| Meghraoui-Kheddar et al. | Two new immature and dysfunctional neutrophil cell subsets define a predictive signature of sepsis useable in clinical practice | |
| Sarmis et al. | Can Hemogram Parameters Predict a Positive PCR Result in COVID-19? | |
| Cheng et al. | Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer | |
| Sarmis et al. | Can Hemogram Parameters Predict a Positive PCR Result in COVID-19? | |
| Saluja et al. | SPARC scoring model: Objective outcome prediction in critically ill COVID-19 patients | |
| Zong et al. | Spatially Distinct Immunothrombotic Signatures in Patients with Pneumonia-Related Acute Respiratory Distress Syndrome: Insights from Lung Alveolar and Blood Circulation Profiles | |
| Arend et al. | A Systematic Comparison of Differential Analysis Methods for CyTOF Data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20141209 |